Michael Erman

Jeff Mason is a White House Correspondent for Reuters and the 2016-2017 president of the White House Correspondents’ Association. He was the lead Reuters correspondent for President Barack Obama's 2012 campaign and interviewed the president at the White House in 2015. Jeff has been based in Washington since 2008, when he covered the historic race between Obama, Hillary Clinton and John McCain. Jeff started his career in Frankfurt, Germany, where he covered the airline industry before moving to Brussels, Belgium, where he covered the European Union. He is a Colorado native, proud graduate of Northwestern University and former Fulbright scholar.

Twitter handle: @jeffmason1

13 Feb 2018

New York sues Weinstein Co., Harvey Weinstein over sexual misconduct

NEW YORK New York's attorney general sued the Weinstein Company and Harvey Weinstein on Sunday alleging years of sexual harassment and misconduct by the movie producer, in a move that could jeopardize talks on a potential sale of the studio. | Video

05 Feb 2018

Bristol-Myers' positive cancer data still lags Merck

Bristol-Myers Squibb Co on Monday provided some positive data on its immuno-oncology drugs for the most lucrative lung cancer market but it fell short of giving clarity on its ability to compete with a rival treatment from Merck & Co Inc

02 Feb 2018

Merck profit beats on lower taxes, overcoming sales miss

Lower taxes helped U.S. drugmaker Merck & Co beat analysts' estimate for fourth-quarter earnings on Friday, offsetting weaker-than-expected sales as some of its products face increasing competition.

31 Jan 2018

Lilly beats estimates; shares fall on diabetes, animal health concerns

Eli Lilly and Co posted better than expected fourth-quarter results, but its shares fell 4 percent on Wednesday due to investor concerns about pricing pressure for its diabetes products and weak sales from its animal health unit.

25 Jan 2018

Biogen forecasts robust 2018 as Spinraza sales surge

U.S. drugmaker Biogen Inc on Thursday posted better-than-expected fourth-quarter revenue and set upbeat expectations for the year on strong sales from its expensive rare-disease treatment Spinraza.

24 Jan 2018

J&J takes $13.6 billion charge related to new U.S. tax law

Healthcare conglomerate Johnson & Johnson on Tuesday took a $13.6-billion charge related to the new U.S. tax law and plans to bring back billions of dollars from overseas immediately.

23 Jan 2018

Celgene to buy Juno for $9 billion to boost cancer pipeline

Celgene Corp will pay $9 billion in cash to buy experimental cancer drugmaker Juno Therapeutics Inc, bulking up its developmental pipeline as it works to reduce reliance on its own cancer treatment Revlimid. | Video

22 Jan 2018

Biotech M&A takes off as Sanofi and Celgene spend $20 billion

Biotech deal activity exploded on Monday with French drugmaker Sanofi and U.S.-based Celgene spending a combined total of more than $20 billion to add new products for haemophilia and cancer to their medicine cabinets. | Video

18 Jan 2018

U.S. court invalidates J&J cancer drug patent, hitting UK's BTG

NEW YORK A U.S. administrative court invalidated a Johnson & Johnson patent on its blockbuster prostate cancer drug Zytiga, bringing rivals closer to selling generic versions and hitting shares in its British partner BTG Plc .

18 Jan 2018

U.S. court invalidates patent on J&J cancer drug Zytiga

NEW YORK A U.S. administrative court on Wednesday invalidated a Johnson & Johnson patent on its blockbuster prostate cancer drug Zytiga, bringing rivals closer to selling generic versions.


  • Asia
  • U.S.
  • Europe
  • Sectors
Stock Search
Sensex 34,142.15 + 322.65 +0.95%
Nikkei 21,892.78 + 156.34 +0.72%
Hang Seng 31,267.17 + 301.49 +0.97%
EUR/INR 79.536 +0.00%
USD/INR 64.700 +0.00%
GBP/INR 90.354 +0.00%
Gold 1,329.80 -0.80 -0.06%
Oil 63.57 +0.80 +1.27%
Corn 366.25 -0.50 -0.14%